DHR · News · 20260804N

Revenue Performance and Mix

DANAHER CORP /DE/ · 2026-08-04 · Importance 31 · Surprise 32

Danaher reported Q2 2026 revenue of $6.26 billion, up approximately 5.5% year over year and above analyst expectations. Core revenue growth and strong Life Sciences performance supported results, while Biotechnology revenue was weaker than expected. The mix shifted toward Diagnostics and Life Sciences as Biotechnology underperformed relative to the company’s other businesses.

Key facts

• A Danaher director, Elias A. Zerhouni, acquired 236.633 phantom shares on July 31, 2026 calculated using Danaher's NYSE closing price of $194.98. source
• After the July 31, 2026 transaction, Elias A. Zerhouni's total phantom-share balance is 18,708.915 units. source